Access Officer (1-year position)
FIND’s vision is of a world where diagnosis guides the way to health for all people. The FIND team is devoted to driving the development, clinical trialing and implementation of innovative diagnostic solutions that can have a high impact on patient care and disease control in low-resource settings. The diseases we work on include tuberculosis, malaria/fever, neglected tropical diseases, as well as AMR and hepatitis C.
The Access Officer will coordinate activities to facilitate introduction and implementation of a new and unique rapid diagnostic test (RDT) being developed by FIND and its partners to simultaneously diagnose malaria and identify patients suspected of having gambiense human African trypanosomiasis (gHAT). The new RDT will be a key tool in elimination of gHAT, and post-elimination surveillance for the disease. The holder of this position will plan its initial market entry. The position will report to the Chief Access Officer, with regular opportunities to work across FIND’s product development and country programs.
FIND is seeking a highly motivated and dynamic individual with proven analytical and communication skills. Candidates should be able to function independently, and be comfortable working in a fast-paced and demanding environment where their input will help drive decision-making.
Position’s Main Tasks:
This position will be focused on the following activities:
- In-country engagement with national gHAT and malaria programs to highlight the utility of the new RDT, its performance, timelines to access, and establish roadmaps for introduction in selected countries. Specifically this area of work will include:
- Mapping of HAT foci against activities of the malaria program in Uganda, Chad, Guinea, Côte d’Ivoire and the Democratic Republic of the Congo, to establish extent of overlap
- Collection and analysis of data on existing national malaria programs, including mapping of testing and treatment services, costs of RDTs and treatments, plans for expansion of treatment, resourcing and timing of budget cycles.
- Detailing the requirements for introduction of the RDT into government, and in particular malaria programs in each country including the regulatory approval process, needed policy changes and approval processes, national strategic planning process and timing, and quality assurance mechanisms
- Defining pathways for introduction of the new RDT to each country
- Establish roadmap in each country for inclusion of the RDT into malaria national strategic plans and donor proposals and/or approval for use in HAT foci. The roadmaps will:
- Use mapping of national malaria program from activity #1 and HAT elimination plans, identify regions where testing using the RDT would be introduced, and define how rollout would be prioritized
- Where gaps exist between regions covered by the national malaria programmes for diagnosis and treatment, and HAT foci, establish detailed accounts of the commodity needs to fill these gaps
- Using historical demand for malaria RDTs and long-term HAT surveillance requirements, estimate the demand for RDTs in each country by site and country per year
- Recommend policies/procedures required to implement the RDT, including quality assurance, confirmatory testing and HAT treatment, training plans and data management
- Develop commodity budgets for malaria testing and treatment, and programmatic needs by country by year, to be incorporated into national budgets and/or donor applications
- Work with endemic countries to provide market entry support for the RDT. Specifically, this will include:
- Mapping the regulatory requirements in each country; providing support for validations and/or other regulatory requirements
- Mapping distribution channels, especially in countries where the manufacturer is not part of the suppliers in the existing national malaria RDT program
- Establishing sales and pricing at both the national and global levels
- Work globally with partners and funders to facilitate uptake of the RDT. Specifically:
- Introduction of the RDT to donors and partner malaria programs
- Identification of pathways to include the RDT in donor and partner malaria programs
- Preparation of detailed plans and budgets to cover the malaria-related costs in HAT foci
- Discussions, with key stakeholders, on the economic and disease coverage trade-offs between HAT and malaria, and opportunities to combine tests to increase coverage and contribute to HAT elimination, and sustaining the elimination.
Professional & Education Background:
- Advanced degree in public health (MPH), business (MBA) or relevant field
- At least 3 years’ experience working in global health
- Proven analytical and quantitative modeling skills, especially with large datasets
- Experience producing high-quality written and presentation-based briefs, proposals, and reports
- Proven ability to work independently and creatively to plan and execute programming and to develop relationships with a far ranging set of stakeholders
- Ability to learn on the job and quickly become proficient in a number of areas
- Strong communication and diplomacy skills with various stakeholders
- Proven technical proficiency with MS Excel, PowerPoint, and Word
- Available for at least 25% travel
- Written and spoken English fluency
- Existing network of relevant contacts
- Fluency in English and good knowledge of French
- Experience introducing/implementing biomedical products such as diagnostics, drugs or vaccines in developing countries
- Experience in diagnostic product development and registration
- Scientific knowledge of malaria/HAT or other infectious diseases
- Operating base in one of the gHAT endemic countries
Please send a motivation letter, a detailed CV and three references to email@example.com.
Deadline to send your application: 17th October 2017
(But don’t wait until the deadline! We will start screening right away and if we find the right person, we will stop searching.)
Please note that only applicants meeting the profile requirements will be personally contacted. Applications sent by recruitment agencies will not be considered.